Liu 等(p. 2243) 对青光眼单眼进展患者的对侧眼进行研究，通过频域光学相干断层扫描（spectral-domain optical coherence tomography [SD OCT]）观察其视网膜神经纤维层（retinal nerve fiber layer [RNFL]）是否进展性变薄；这些病例均通过视野或视神经照片诊断。研究者发现对侧眼RNFL缺失见于大多数患者。该前瞻性纵向队列研究共纳入173名患者的346例眼（基线时118例为青光眼，228例为可疑青光眼）。平均随访时间为3.5±0.7年。在其中39名患者，传统诊断方法发现单眼进展，而SD OCT发现对侧眼平均RNFL厚度下降（−0.71±0.09 μm/年）。另一方面，传统诊断方法并未发现其余134名患者出现进展——然而其RNFL厚度在随访期变薄（−0.71±0.09 μm/年）。

Liu et al (p. 2243) used spectral-domain optical coherence tomography (SD OCT) to examine whether progressive thinning of the retinal nerve fiber layer (RNFL) occurs in the contralateral eye of glaucoma patients with unilateral progression that was originally diagnosed via visual fields or optic disc photography. They noted RNFL loss in the fellow eyes of a substantial number of patients. This prospective longitudinal cohort study involved 346 eyes of 173 patients (118 eyes with glaucoma and 228 eyes with suspect glaucoma at baseline).

In their review, Yeh et al1 thoroughly assessed the available evidence regarding the safety and efficacy of therapies for macular edema (ME) associated with central retinal vein occlusion (CRVO). Of the treatments evaluated, anti-vascular endothelial grow factor (VEGF) pharmacotherapy was the most common intervention. The authors conducted an excellent comprehensive presentation and discussion of the Cruise, Copernicus, Galileo, and Swedish trials, providing level 1 evidence supporting the use of intravitreal injections with ranibizumab (Lucentis, Genentech, Inc., South San Francisco, CA), aflibercept (IVA; Eylea, Regeneron Pharmaceuticals, Inc., Tarrytown, NY), and bevacizumab (Avastin, Genentech, Inc., San Francisco, CA) in patients with ME after CRVO.

Ophthalmic Technology Assessments (OTAs) have been a regular feature of Ophthalmology for more than 25 years. This month we publish what I imagine will be one of our most provocative OTAs, “Topical Nonsteroidal Anti-Inflammatory Drugs and Cataract Surgery” (see p. 2159). Therefore, as current Chair of the OTA Committee, I thought it would be timely to review the history of OTAs and the process by which they arise. Flora Lum, MD, Vice President, Quality and Data Science, at the American Academy of Ophthalmology (AAO), and Doris Mizuiri, Editorial/Production Coordinator with the AAO were instrumental in providing me with much of the background material.

The recent Ebola virus disease (EVD) epidemic in West Africa has captured the world's attention. Ebola virus disease is a multisystem hemorrhagic fever with remarkably high mortality. Patients typically present with high fever and flu-like symptoms, progressing to diarrhea, vomiting, and disseminated hemorrhage with multisystem organ failure. Overall mortality is greater than 40%, with most patients dying within 1 month of contracting the virus. As of August 2015, there have been more than 27 000 reported cases worldwide resulting in more than 11 000 deaths, with more than 10 000 of these cases occurring during the 2014 to 2015 epidemic.

We read with interest the article titled “Threat to fixation at diagnosis and lifetime risk of visual impairment in open-angle glaucoma” by Peters et al.1 In a retrospective study, they evaluated the association between threat to fixation (TTF) at diagnosis and low vision and blindness in a group of glaucoma patients with whom they followed up until death. They found TTF was not an independent risk factor for developing glaucoma blindness or low vision when the disease severity stage (expressed in terms of mean deviation) at the time of diagnosis was accounted for.